Voucher and NEW Patient Copay Assistance information is now available here

The 1st VMAT2 inhibitor approved for both TD and HD chorea1

HD Chorea Campaign Banner
HD Chorea Campaign Banner

For adults with TD or HD chorea

Make a

move that



*Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.2,3

Patients in the pivotal and 3-year studies received the AUSTEDO BID formulation.1,4

Orange Video Icon

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.6

AIMS, Abnormal Involuntary Movement Scale; HD, Huntington’s disease; TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003-2010. 4. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999 5. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 6. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.